Important safety information to minimise the risk of immune-related adverse reactions

Similar documents
system to help fight cancer Working with your immune

system to help fight cancer Working with your immune

Package leaflet: Information for the patient. KEYTRUDA 25 mg/ml concentrate for solution for infusion pembrolizumab

Package leaflet: Information for the patient. KEYTRUDA 50 mg powder for concentrate for solution for infusion pembrolizumab

For the Patient: ULUAVPMB

For the Patient: USMAVPEM

For the Patient: USMAVNIV

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

For the Patient: USMAVFIPI

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor

Package leaflet: Information for the patient. Bavencio 20 mg/ml concentrate for solution for infusion avelumab

Have a healthy discussion. Use this guide to start a. conversation. with your. healthcare provider

What do I need to tell my doctor BEFORE I take this drug?

Nivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions

Your treatment with XELJANZ

YOUR GUIDE TO TECENTRIQ (atezolizumab) non-small cell lung cancer (NSCLC)

What do I need to tell my doctor BEFORE I take this drug?

(sunitinib malate) for Kidney Cancer

Talking about your treatment. A guide to the conversations you may have before starting LEMTRADA

Package leaflet: Information for the user. Cyclizine Lactate 50 mg/ml Injection

For the Patient: Rituximab injection Other names: RITUXAN

Giving appropriate patients another chance to fight OPDIVO

MEDICATION GUIDE PegIntron (peg-in-tron) (Peginterferon alfa-2b) for injection, for subcutaneous use

Eloxatin Oxaliplatin concentrated solution for injection

Nivolumab. Nivolumab

Do not g ive this drug if your child has an infection or any inflammation.

What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

Summary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO. Avelumab 200 mg/10 ml. Concentrate for Solution for Infusion

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. SYLVANT pronounced SILL-vant siltuximab for injection

Chelation therapy for iron overload in sickle cell and thalassaemia

What is the most important information I should know about bortezomib? What should I discuss with my healthcare provider before receiving bortezomib?

PACKAGE LEAFLET: INFORMATION FOR THE USER

For the Patient: LUAVPG (Carboplatin Option)

Package leaflet: Information for the patient. Abacavir 300 mg Film-coated Tablets

PACKAGE LEAFLET: INFORMATION FOR THE USER

METHYLDOPA 250 mg Film-coated Tablets

For the Patient: Lenalidomide Other names: REVLIMID

Summary of the risk management plan (RMP) for Opdivo (nivolumab)

For the Patient: Fludarabine injection Other names: FLUDARA

Package leaflet: Information for the patient. Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam

Discussing TECENTRIQ (atezolizumab) with your healthcare team

NUCALA. mepolizumab. Patient Support

Some general information on hepatitis A infection is given at the end of this leaflet.

Inlyta (axitinib) for Kidney Cancer

Package Leaflet: Information for the User

For the Patient: Amsacrine Other names: AMSA PD

What is the most important information I should know about tenofovir? What should I discuss with my healthcare provider before taking tenofovir?

This leaflet answers some common questions about HERCEPTIN SC. It does not contain all the available information.

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.

All medicines have risks and benefits. Your doctor has weighed the risks of you being given Mabthera SC against the benefits expected for you.

For the Patient: Cyclosporine injection Other names: SANDIMMUNE I.V.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium)

PATIENT INFORMATION LEAFLET

Package leaflet: Information for the patient

Actemra concentrate for intravenous infusion

acting aggressive, being angry or violent yourself, or feeling hopeless)

For the Patient: LUAVPEM

For the Patient: Trastuzumab emtansine Other names: KADCYLA

HERNOVIR 200 mg tablets

If you have any questions about how Letrozole Tablets works or why this medicine has been prescribed for you, ask your doctor.

If you have any concerns about using this medicine, ask your doctor or pharmacist.

Nilotinib (nil ot' i nib) is a drug that is used to treat some types of cancer. It is a capsule that you take by mouth.

Package leaflet: Information for the user

WARNINGS AND PRECAUTIONS - COMBINATION OF OPDIVO AND YERVOY

What are some things I need to know or do while I take

D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin

For the Patient: Eribulin Other names: HALAVEN

For the Patient: Mitoxantrone Other names:

MEDICATION GUIDE. BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use

Medication information for patients and families

Tuscarawas County Health Department. Vivitrol Treatment Consent

For the Patient: Ponatinib Other names: ICLUSIG

Package leaflet: Information for the user. HBVAXPRO 10 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna)

For the Patient: GIPAJGEM Other Names: Adjuvant chemotherapy for pancreatic cancer using Gemcitabine

For the Patient: GIPGEM Other Names: Metastatic cancer of the pancreas, gallbladder or bile duct.

Summary of the risk management plan (RMP) for Nivolumab BMS (nivolumab)

What do I need to tell my doctor BEFORE I take this drug? If you have an allerg y to ofatumumab or any other part of this drug.

It may be g iven to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug?

Package leaflet: Information for the user. DaunoXome Injection 2mg/ml Concentrate for Solution for Infusion Daunorubicin

Perjeta Contains the active ingredient pertuzumab (rch)

Patient leaflet: Information for the user. Cytarabine 20mg/ml and 100mg/ml Solution for infusion or injection (Cytarabine)

Preparing for Your Immune Checkpoint Inhibitor (CPI) Treatment

Methotrexate. About This Drug. Possible Side Effects. Warnings and Precautions

You should read this leaflet carefully and keep it in a safe place to refer to it later. WHAT IS OPDIVO USED FOR

For the Patient: Bendamustine Other names: TREANDA

MEDICATION GUIDE SUTENT

Sorafenib (so-ra-fe-nib) is a drug that is used to treat many types of cancer. It is a tablet that you take by mouth.

Inflectra for Crohn s disease

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen

Package leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate

For the Patient: LUPUPE (Carboplatin Option)

Transcription:

Your Guide to KEYTRUDA (pembrolizumab) Important safety information to minimise the risk of immune-related adverse reactions Information for Patients This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store for how to report side effects. Adverse events should also be reported to MSD on Tel: 01992 467272.

Introduction Your doctor has prescribed KEYTRUDA (pembrolizumab) to treat your cancer. Please refer to the Patient Information Leaflet to read what pembrolizumab is and what it is used for. This brochure will serve as a guide to your treatment, including what to expect while you are taking this medicine. This guide will explain some of the side effects that might occur while you undergo treatment with pembrolizumab, and how to check for them. You will also learn why it is important to report any symptoms to your doctor right away. Glue Alert Card Here DOCTOR STAMP 2

About pembrolizumab Pembrolizumab is a medicine used to treat some types of cancer. This treatment may have side effects. Pembrolizumab is a type of therapy that works by helping your immune system fight your cancer. Before you start pembrolizumab Tell your doctor about any medicines you are taking, have recently taken, or might take. Make sure your doctor knows if you: Have an autoimmune disease (a condition where the body attacks its own cells) Have pneumonia or inflammation of the lungs (called pneumonitis) Were previously given ipilimumab, another medicine for treating a selected type of cancer, and experienced serious side effects because of that medicine Had an allergic reaction to other monoclonal antibody therapies Have or have had chronic viral infection of the liver, including hepatitis B (HBV) or hepatitis C (HCV) Have human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS) Have liver damage Have kidney damage Have had a solid organ transplant Are taking other medicines that make your immune system weak. Examples of these may include corticosteroids, such as prednisone Are taking, have recently taken, or might take any other medicines Are pregnant, think you may be pregnant, or are planning to have a baby Are a woman who could become pregnant, you must use adequate birth control while you are being treated with pembrolizumab and for at least 4 months after your last dose Are breast-feeding or plan to breast-feed 3

What you should know about your treatment How you are given pembrolizumab Pembrolizumab will be given to you in a hospital or clinic under the supervision of an experienced doctor. Your doctor will give you pembrolizumab through an infusion into a vein. The infusion will last for 30 minutes. Please refer to the Patient Information Leaflet for the recommended dose of pembrolizumab. Sometimes the tumour may get bigger for the first few months before it starts to shrink or new tumours may appear. If your tumour seems to get worse at first after starting treatment with pembrolizumab, your doctor may continue your treatment if your health is stable, and will check again to see if you are responding. It is important that you visit your doctor for your scheduled appointments so your doctor can check your progress and administer pembrolizumab. If you are unable to keep an appointment, call your doctor right away to reschedule. Pembrolizumab can cause serious side effects that need to be treated straight away Possible side effects Like all medicines, pembrolizumab can cause side effects, although not everyone gets them. When you take pembrolizumab, you can have some serious side effects. You may experience more than one side effect at the same time. It is very important to tell your doctor about any symptoms you notice while taking pembrolizumab. Your doctor may give you other medicines in order to prevent more severe complications and reduce your symptoms. Your doctor may withhold the next dose of pembrolizumab or stop your treatment. 4

Tell your doctor right away if you have any of these symptoms Side effect Signs or symptoms Lung problems (inflammation of the lungs, possibly fatal) Intestinal problems (inflammation of the intestines) Liver problems (inflammation of the liver) Kidney problems (inflammation of the kidney) Hormone gland problems (especially thyroid, pituitary, adrenal) Type 1 diabetes Skin problems (inflammation of the skin, possibly fatal) Problems in other organs Infusion reactions Shortness of breath Chest pain Coughing Diarrhoea or more bowel movements than usual Stools that are black, tarry, sticky, or contain blood or mucus Severe stomach pain or tenderness Nausea or vomiting Nausea or vomiting Feeling less hungry Pain on the right side of the stomach Yellowing of your skin or whites of eyes Dark urine Bleeding or bruising more easily than normal Changes in the amount or colour of your urine Rapid heart beat Weight loss or weight gain Increased sweating Hair loss Feeling cold Constipation Deeper voice Muscle aches Dizziness or fainting Headaches that will not go away or unusual headache Feeling more hungry or thirsty Needing to urinate more often Weight loss Rash Itching Skin blistering Peeling or sores Ulcers in mouth or in lining of nose, throat, or genital area Eyes: changes in eyesight Muscles: pain or weakness Heart: shortness of breath, irregular heartbeat, feeling tired, or chest pain Pancreas: abdominal pain, nausea, and vomiting Nerves: temporary inflammation that causes pain, weakness and paralysis in the arms and legs Rejection of a solid organ transplant after receiving pembrolizumab (tell your doctor if you have had a solid organ transplant) Shortness of breath Itching or rash Dizziness Fever Complications of stem cell transplant that uses donor stem cells (allogeneic) after treatment with pembrolizumab. These complications can be severe and can lead to death. Your doctor will monitor you for signs of these complications. Tell your transplant doctor that you have received pembrolizumab in the past. If you have any side effects, including any possible side effects not listed here, contact your doctor. 5

Watching for side effects It is important to be aware of symptoms If you notice any symptoms while receiving pembrolizumab, you should talk to your doctor right away. Be aware that side effects may still occur after receiving the final dose of pembrolizumab. Certain medications, such as corticosteroids, may be used to prevent more severe complications and reduce your symptoms. Your doctor may delay or completely stop your treatment if your side effects are too severe. Do not attempt to diagnose or treat side effects yourself. What to do if symptoms occur when you are away from home It is important that you contact your doctor whenever symptoms occur. Always carry your Alert Card with your doctor s contact information so that he or she may be reached in case of emergency. The Alert Card contains important information about symptoms that need to be reported immediately to the doctor or nurse treating you while you are away from home. It also alerts other doctors that you are being treated with pembrolizumab. Carry your Alert Card with you at all times. 6

Don t miss an appointment for treatment with pembrolizumab If you stop or interrupt your treatment, it may stop the effect of the medicine. Don t stop your treatment with pembrolizumab unless you have discussed this with your doctor. Please try your best to keep all of your appointments, and reschedule as soon as possible if you miss one. Contact your doctor immediately if you experience any side effects, including those not listed in this brochure. Your tumour may first grow in size or new ones may appear before the positive effects of pembrolizumab begin to occur. It is important that you receive your medicine as prescribed to get the most out of your treatment. Please contact your doctor if you have any questions about pembrolizumab or how it works. 7

Remember Pembrolizumab is a type of therapy that works by helping your immune system fight your cancer. Pembrolizumab is given through an infusion into your vein over 30 minutes, usually every 3 weeks. This type of therapy can sometimes have side effects. With pembrolizumab, certain side effects can occur that may be serious. Contact your doctor right away if you experience any side effects. Speak with your doctor if you have any questions about pembrolizumab or how it works. Where to find further information For more information, consult the KEYTRUDA Patient Information Leaflet (PIL) at www.medicines.org.uk/emc or call MSD Medical Information on Tel: 01992 467272. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Reporting side effects Please report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. Copyright 2017 Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU. Registered in England No. 820771. All rights reserved. Date of preparation: August 2017. ONCO-II-028-001.